scispace - formally typeset
Open AccessJournal ArticleDOI

Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling

TLDR
Left ventricular end-diastolic and end-systolic volume and ejection fraction data provide support for the beneficial effects of therapeutic agents such as angiotensin-converting enzyme (ACE) inhibitors and beta-adrenergic blocking agents on the remodeling process.
About
This article is published in Journal of the American College of Cardiology.The article was published on 2000-03-01 and is currently open access. It has received 2215 citations till now. The article focuses on the topics: Ventricular remodeling & Ejection fraction.

read more

Citations
More filters
Journal ArticleDOI

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.

TL;DR: Valsartan significantly reduces the combined end point of mortality and morbidity and improves clinical signs and symptoms in patients with heart failure, when added to prescribed therapy, and raises concern about the potential safety of this specific combination.
Journal ArticleDOI

Myocardial Matrix Remodeling and the Matrix Metalloproteinases: Influence on Cardiac Form and Function

TL;DR: The purpose of this review is to examine and redefine the myocardial matrix as a critical and dynamic entity with respect to the remodeling process encountered with MI, hypertension, or cardiomyopathic disease, and to dispel the historical belief that the myCardial matrix is a passive structure.
References
More filters
Journal ArticleDOI

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

TL;DR: The addition of enalapril to conventional therapy significantly reduced mortality and hospitalizations for heart failure in patients with chronic congestive heart failure and reduced ejection fractions.
Journal ArticleDOI

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

Åke Hjalmarson, +350 more
- 12 Jun 1999 - 
TL;DR: Metoprolol controlled release/extended release (CR/XL) once daily in addition to standard therapy improved survival and the drug was well tolerated.
Journal ArticleDOI

Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)

TL;DR: The addition of enalapril to conventional therapy in patients with severe congestive heart failure can reduce mortality and improve symptoms, and the effect seems to be due to a reduction in death from progression of heart failure.
Journal ArticleDOI

The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial

TL;DR: Beta-blocker therapy had benefits for survival in stable heart-failure patients and should not be extrapolated to patients with severe class IV symptoms and recent instability because safety and efficacy has not been established in these patients.
Related Papers (5)